[1] J. W. Sander and S. D. Shorvon, “Epidemiology of the Epilepsies,” Journal of Neurology Neurosurgery & Psychiatry, Vol. 61, No. 5, 1996, pp. 433-443. http://dx.doi.org/10.1136/jnnp.61.5.433
[2] N. Senanayake and G. C. Roman, “Epidemiology of Epilepsies in Developing Countries,” WHO Bulletin, Vol. 71, No. 2, 1993, pp.247-258.
[3] O. Devinsky, “Cognitive and Behavioral Effects of Antiepileptic Drugs,” Epilepsia, Vol. 36, Suppl. s2, 1995, pp. S46-S65. http://dx.doi.org/10.1111/j.1528-1157.1995.tb05999.x
[4] G. L. Holmes, “Critical Issues in the Treatment of Epilepsy,” American Journal of Hospital Pharmacist, Vol. 50, Suppl. 5, 1993, pp. S5-S16.
[5] R. H. Mattson, “Efficacy and Adverse Effects of Established and New Antiepileptic Drugs,” Epilepsia, Vol. 36, Suppl. S2, 1995, S13-S26. http://dx.doi.org/10.1111/j.1528-1157.1995.tb05995.x
[6] E. B. Samren, C. M. V. Duijn, G. C. M. L. Christiaens, A. Hofman and D. Lindhout, “Antiepileptic Drug Regimens and Major Congenital Abnormalities in the Offspring,” Annals of Neurology, Vol. 46, No. 5, 2001, pp. 739-746. http://dx.doi.org/10.1002/1531-8249(199911)46:5<739::AID-ANA9>3.0.CO;2-2
[7] M. C. Smith and T. P. Bleck, “Convulsive Disorders: Toxicity of Anticonvulsants,” Clinical Neuropharmacology, Vol. 14, No. 2, 1991, pp. 97-115. http://dx.doi.org/10.1097/00002826-199104000-00001
[8] I. I. Ali, L. Schuh, G. L. Barkley and J. R. Gates, “Antiepileptic Drugs and Reduced Bone Mineral Density,” Epilepsy & Behavior, Vol. 5, No. 3, 2004, pp. 296-300. http://dx.doi.org/10.1016/j.yebeh.2004.02.005
[9] D. Heaney, “The Pharmacoeconomics of the New Antiepileptic Drugs,” Epilepsia, Vol. 40, Suppl. s8, 1999, pp. 25-31. http://dx.doi.org/10.1111/j.1528-1157.1999.tb00944.x
[10] Z. Razi, “Al-Hawi-Fil-Tib (Urdu Translation),” CCRUM Publication, New Delhi, 1997.
[11] I. Baitar, “Al-Jam-e-ul-Mufradat-Al-Adviah-Wal-Aghziya (Urdu translation),” CCRUM publication, New Delhi, 1999.
[12] N. G. Khan, “Khazainul Adviah,” Matba Munshi Naval Kishore, Lucknow, 1921.
[13] D. Bendjeddou, K. Lalaoui and D. Satta, “Immunostimulating Activity of the Hot Water-Soluble Polysaccharide Extracts of Anacyclus pyrethrum, Alpinia galanga and Citrullus colocynthis,” Journal of Ethnopharmacology, Vol. 88, No. 2-3, 2003, pp. 155-160. http://dx.doi.org/10.1016/S0378-8741(03)00226-5
[14] V. Sharma, M. Thakur, N. S. Chauhan and V. K. Dixit, “Evaluation of the Anabolic, Aphrodisiac and Reproductive Activity of Anacyclus pyrethrum DC in Male Rats,” Scientia Pharmaceutica, Vol. 77, 2009, pp. 97-110. http://dx.doi.org/10.3797/scipharm.0808-14
[15] J. M. Gulland and G. U. Hopton, “Pellitorine, the Pungent Principle of Anacyclus pyrethrum,” Journal of Chemical Society, 1930, pp. 6-11. http://dx.doi.org/10.1039/jr9300000006
[16] R. S. Burden and L. Crombie, “Amides of Vegetable Origin. Part XII. A New Series of Alka-2, 4-Dienoic Tyramine-Amides from Anacyclus pyrethrum D. C. (Compositae),” Journal of the Chemical Society C: Organic, No. 19, 1969, pp. 2477-2481. http://dx.doi.org/10.1039/j39690002477
[17] “The Wealth of India,” CSIR Publication, New Delhi, 1985.
[18] K. Sukumaran and R. Kuttan, “Inhibition of Tobacco-Induced Mutagenesis by Eugenol and Plant Extracts,” Mutation Research/Genetic Toxicology, Vol. 343, No. 1, 1995, pp. 25-30. http://dx.doi.org/10.1016/0165-1218(95)90059-4
[19] A. Gorji and M. K. Ghadiri, “History of Epilepsy in Medieval Iranian Medicine,” Neuroscience & Biobehavoiral Reviews, Vol. 25, No. 5, 2001, pp. 455-461. http://dx.doi.org/10.1016/S0149-7634(01)00025-2
[20] D. Vohora, S. N. Pal and K. K. Pillai, “Thioperamide a Selective Histamine H3 Receptor Antagonist, Protects Against PTZ-Induced Seizures in Mice,” Life Science, Vol. 66, No. 22, 2000, pp. 297-301. http://dx.doi.org/10.1016/S0024-3205(00)00548-8
[21] Y. Kitano, C. Usui, K. Takasuna, M. Hirohashi and M. Nomura, “Increasing-Current Electroshock Seizure Test: A New Method for Assessment of Antiand Pro-Convulsant Activities of Drugs in Mice,” Journal of Pharmacological and Toxicological Methods, Vol. 35, No. 1, 1996, pp. 25-29.
http://dx.doi.org/10.1016/1056-8719(95)00115-8
[22] A. Ali, F. J. Ahmad, K. K. Pillai and D. Vohora, “Evidence of the Antiepileptic Potential of Amiloride with Neuropharmacological Benefits in Rodent Models of Epilepsy and Behavior,” Epilepsy & Behaviour, Vol. 5, No. 3, 2004, pp. 322-328. http://dx.doi.org/10.1016/j.yebeh.2004.01.005
[23] T. C. M. Lima, G. S. Morato and R. N. Takahashi, “Evaluation of the Control Properties of Artemisia Verloturum,” Planta Medica, Vol. 59, No. 4, 1993, pp. 326-329. http://dx.doi.org/10.1055/s-2006-959692
[24] H. H. Frey and W. Loscher, “Di-n-Propyletic Acid-Profile of Anticonvulsant Activity in Mice,” Arzneimittelforschung, Vol. 26, 1976, pp. 299-301.
[25] F. Baldino and H. M. Geller, “Sodium Valproate Enhancement of Gamma-Aminobutyric Acid (GABA) Inhibition: Electro-Physiological Evidence for Anticonvulsant Activity,” The Journal of Pharmacology and Experimental Therapeutics, Vol. 217, No. 2, 1981, pp. 445-450.
[26] J. Szabadics and L. Erdelyi, “Pre-and Postsynaptic Effect of Eugenol and Related Compounds on Helix pomatia L. Neurons,” Acta Biologica Hungarica, Vol. 51, No. 2-4, 2000, pp. 265-273.
[27] M. B. Wie, M. H. Won, K. H. Lee, J. H. Shin, J. C. Lee, H. W. Suh, D. K. Song and Y. H. Kim, “Eugenol Protects Neuronal Cells from Excitotoxic and Oxidative Injury in Primary Cortical Cultures,” Neuroscience Letters, Vol. 225, No. 4, 1997, pp. 93-96. http://dx.doi.org/10.1016/S0304-3940(97)00195-X
[28] M. H. Won, J. C. Lee, Y. H. Kim, D. K. Song, H. W. Suh, Y. S. Oh, J. H. Kim, T. K. Shin, Y. J. Lee and M. B. Wie, “Post-Ischemic Hypothermia Induced by Eugenol Protects Hippocampal Neurons from Global Ischemia in Gerbils,” Neuroscience Letters, Vol. 254, No. 2, 1998, pp. 101-104. http://dx.doi.org/10.1016/S0304-3940(98)00664-8